Penn. Medicaid savings from Pfizer Procardia XL to Bayer Adalat CC switch found in retrospective study.

Executive Summary

BAYER ADALAT CC/PFIZER PROCARDIA XL PENNSYLVANIA MEDICAID SWITCH STUDY found that the state's Medicaid program could save "more than $2.5 mil. per year" by switching hypertensive patients without angina from Procardia XL to Adalat CC, according to a study published in a recent issue of Clinical Therapeutics. The two once-a-day nifedipine calcium channel blockers were examined through a retrospective analysis of Medicaid claims data from 1993. Miles (now Bayer) Pharmaceutical Division of Health and Economics Outcomes Research staffer Robert Simons was the principal investigator.